Straits Times Index
3,394.21 +17.02 (+0.50%) S&P 500
4,070.56 +10.13 (+0.25%) Dow
33,978.08 +28.67 (+0.08%) Nasdaq
11,621.71 +109.30 (+0.95%) BTC-USD
23,622.41 +618.05 (+2.69%) CMC Crypto 200
526.66 +9.65 (+1.87%)
Roche Holding AG (RHHVF)
- Zacks
Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal
Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.
- Business Wire
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
SOUTH SAN FRANCISCO, Calif., January 19, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study is evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence. The Tec
- Zacks
The Zacks Analyst Blog Highlights UnitedHealth Group, The Coca-Cola, Roche Holding, Lam Research and Valero Energy
UnitedHealth Group, The Coca-Cola, Roche Holding, Lam Research and Valero Energy are part of the Zacks top analyst blog.
